tyrosine kinase inhibitor(English)
- molecular targeted therapy based on TKIs has improved clinical outcomes in a large number of NSCLC patients with advanced disease, enabling significantly longer progression-free survival
- CMR, CRS, cTn, cTnI, CTRCD, ECG, GLS, GnRH, HbA1c, HSCT, HER2, ICI, IHD, IMID, LAVI, LVEF, MEK, MM, NT-proBNP, PI, RVEDV, TAPSE, TTE, VEGFi, PI, SACT, mRCC, ALK, BRAF, EGFR, MET, NGS, NSCLC, PFS, ROS1, sWGS, T790M, ACHD, ADT, AF, AIC, BP, BTKi, CAC, CAD, CAR-T, CIED, CLL
- Therapeutic approaches, Oncology, Pulmonology, Cardiology
- https://doi.org…cancer.2017.764
- https://doi.org…325-021-01657-2
- https://doi.org…0/cells11182871
- https://doi.org…cao.2024.07.017